Speaker Profile
Ph.D., CEO, Founder, Alida Biosciences
Biography
Gudrun specializes in developing advanced genomics platforms, drawing onher experience in NGS development and background in biophysics andbiochemistry. She has made significant contributions to the field, including the development of the Nova Seq platform at Illumina, and the Aviti platform at Element. In the startup space, she played a key role insecuring Series B funding for Encodia through her work in proteomics. Currently, as the founder of Alida Biosciences, Gudrun is focused oncreating novel RNA epitranscriptomic technologies designed to advancebeyond primary transcriptomic sequence analysis, to empower a new frontierof RNA biology and enhancement of multi-omic studies.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia University
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
Keynote: The Industrialization of Cell Therapy:From Autologous Pioneers to Allogeneic Frontiers
• Arie S. Belldegrun, Allogene Therapeutics
Next Generation CAR-T Cell Therapies: Expanding Targets and Enhancing Designs
• Chair: David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Stanford
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• Zach Roberts, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Smart Scaling: Leverating AI & Automation to De-Risk Advanced Therapy Manufacturing
• Chair: Stacie Calad-Thomson
• Samuel Rodriques, FutureHouse
• Manuel Leonetti, Biohub
• Fabian Gerlinghaus, Cellares
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
In-Vivo Myeloid Programming: Engineering the Innate Immune System for Solid Tumor Therapy
• Daniel Getts, Myloid Therapeutics
Operationalizing Cell & Gene Therapy Trials in a Large Health System
•Snehit Prabhu, Stanford
Gene Editing & Synthetic Biology for Therapy
• Chair: Trevor Martin, Mammoth Biosciences
• Ken Drazan, ArsenalBio
• Lynn Seely, Lyell
• Kole T. Roybal, Parker Institute
• David Kirn, 4DMT
